Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 716
National Institute for Health and Care Excellence (NICE)
Record ID 32018011759
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta716
Year Published:
2021
URL for published report:
https://www.nice.org.uk/guidance/ta716
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Colorectal Neoplasms
- Nivolumab
- Ipilimumab
- Antineoplastic Agents, Immunological
- Antibodies, Monoclonal, Humanized
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.